• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant

 

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response 

by Syed Hamza Sohail 03/29/2023 Leave a Comment

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response 

What You Should Know: Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More

NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D

by Fred Pennic 03/21/2023 Leave a Comment

NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D

What You Should Know: - NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. - Part of NVIDIA AI Foundations, the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery. It
Read More

Protai Raises $20M to Build an Oncology Drug Discovery Pipeline

by Syed Hamza Sohail 03/15/2023 Leave a Comment

Protai Raises $20M to Build an Oncology Drug Discovery Pipeline

What You Should Know: - Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M. - The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More

Tempus, Pfizer Partner to Advance Oncology Therapeutic Development

by Fred Pennic 02/28/2023 Leave a Comment

Tempus, Pfizer Partner to Advance Oncology Therapeutic Development

What You Should Know: - Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology. - Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. -
Read More

Report: Pharma R&D ROI Falls to Lowest Level in 13 Years

by Syed Hamza Sohail 02/16/2023 Leave a Comment

Pharma R&D ROI Falls to Lowest Level in 13 Years

What You Should Know: - Deloitte Centre for Health Solutions releases its thirteenth annual report, ‘Seize the Digital Momentum: Measuring the return from pharmaceutical innovation 2022’ that explores the performance of the biopharmaceutical industry (bio Pharma) and its ability to generate returns from investment in innovative new medicines. - Since 2021, much of the world has successfully adjusted to life where COVID-19 is more endemic as vaccines and treatments reduced the risk and
Read More

BenchSci Launches ‘Map’ of Biology Research Platform for Pharmaceutical Research

by Fred Pennic 02/13/2023 Leave a Comment

BenchSci Launches ‘Map’ of Biology Research Platform for Pharmaceutical Research

What You Should Know: - BenchSci, a Canadian-based tech company and leader in AI solutions for drug discovery recently launches a Google-backed 'map' of biology research platform, ASCEND™ by BenchSci, to understand the underlying biology. - The patented machine learning platform reads millions of published and previously hidden experiment external and internal data sources to create a map that allows scientists to more quickly (50% more) and accurately understand the biological
Read More

7 Life Sciences Executive Predictions to Watch in 2023

by Fred Pennic 01/13/2023 Leave a Comment

7 Executive Life Sciences Predictions to Watch in 2023

Tracy Curley, CFO and interim CEO at iSpecimen Focusing on the macroeconomic environment, which remains impacted by the lingering COVID-19 pandemic, there continues to be uncertainty about the strength of the global, Asia Pacific, UK and US economies. High-interest rates and a potential recession remain a concern for all market participants. At ISPC, we are closely monitoring the pace of specimen transactions. We believe that this industry can be resilient through a continued economic
Read More

Merck Invests in Gesund, Launches Medical AI Platform on AWS

by Syed Hamza Sohail 12/21/2022 Leave a Comment

Merck Invests in Gesund, Launches Medical AI Platform on AWS

What You Should Know: - Gesund, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced the securing of a strategic investment from Merck as well as a launch of a new commercial platform on Amazon Web Services Marketplace. - While terms of the investment are not being disclosed, the news signals support for the company's approach as it launches a first of its kind commercial platform on Amazon Web Services Marketplace, immediately
Read More

Analysis: RSNA 2022: Predictions vs Reality

by Steve Holloway, Director at Signify Research 12/13/2022 Leave a Comment

RSNA 2022: Predictions vs Reality

Much has already been written about attendance at RSNA, but from a first-hand perspective, RSNA 2022 could be regarded as a step back toward “normal”. Amongst mostly bustling halls, vendors reported very positive feedback on the volume and quality of customer meetings, with one prominent global imaging vendor citing “We’re signing deals here at the show again – things are looking up”.  Against this positive backdrop, however, the stark challenges facing radiology in a post-COVID world were
Read More

Vevo Launches with $12M to Scale Vivo Data Generation to Discover Better Drugs

by Fred Pennic 12/08/2022 Leave a Comment

Vevo Launches with $12M to Scale Vivo Data Generation to Discover Better Drugs

What You Should Know: - Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients. - Vevo is the first platform to make in vivo data generation scalable with single-cell precision + will create the world’s largest atlas of how drugs interact with patient cells. In a single in vivo
Read More

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |